Search Results - "Gengwei Huo"

Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.

Authors: Gengwei Huo Ying Song Peng Chen

Source: Journal of Gynecologic Oncology. Nov2024, Vol. 35 Issue 6, p1-11. 11p.

Cost-effectiveness of atezolizumab plus chemotherapy for advanced/ recurrent endometrial cancer.

Authors: Gengwei Huo Ying Song Peng Chen

Source: Journal of Gynecologic Oncology. Sep2024, Vol. 35 Issue 5, p1-14. 14p.

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

Authors: Gengwei Huo Wenjie Liu Peng Chen

Source: Journal of Gynecologic Oncology. Sep2024, Vol. 35 Issue 5, p1-12. 12p.

High incidence and reversible bradycardia events following alectinib initiation.

Authors: Dongqi Yuan Fuyi Zhu Ran Zuo et al.

Source: Thoracic Cancer. Feb2023, Vol. 14 Issue 5, p479-488. 10p.

Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2-positive non-small cell lung cancer: A single-arm systematic review and meta-analysis.

Authors: Zhao, Fanfei Niu, Tantan Zheng, Yang et al.

Source: Oncology Letters. Oct2025, Vol. 30 Issue 4, pN.PAG-N.PAG. 1p.

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.

Authors: Liu, Wenjie Huo, Gengwei Chen, Peng

Source: BMC Cancer. 5/19/2023, Vol. 23 Issue 1, p1-17. 17p.

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.

Authors: Huo, Gengwei Liu, Wenjie Chen, Peng

Source: BMC Cancer. 2/13/2023, Vol. 23 Issue 1, p1-16. 16p.

Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Authors: Huo G Wang X Song Y et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2026 Apr 13; Vol. 17, pp. 1684603. Date of Electronic Publication: 2026 Apr 13 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.

Authors: Cai H Fang L Lin J et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2024 Oct 21; Vol. 15, pp. 1476256. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis.

Authors: Song D Hou S Ma N et al.

Source: Frontiers in immunology [Front Immunol] 2024 Nov 01; Vol. 15, pp. 1485303. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024).

Publication Type: Meta-Analysis; Systematic Review; Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.

Authors: Liu W Huo G Chen P

Source: Frontiers in public health [Front Public Health] 2024 Feb 15; Vol. 12, pp. 1213318. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.

Authors: Liu W Huo G Chen P

Source: Frontiers in immunology [Front Immunol] 2022 Jun 21; Vol. 13, pp. 909027. Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).

Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Authors: Liu W Huo G Chen P

Source: Frontiers in pharmacology [Front Pharmacol] 2023 Jul 20; Vol. 14, pp. 1163381. Date of Electronic Publication: 2023 Jul 20 (Print Publication: 2023).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Oncogenic role of TWF2 in human tumors: A pan-cancer analysis.

Authors: Liu W Huo G Chen P

Source: Open medicine (Warsaw, Poland) [Open Med (Wars)] 2022 Sep 05; Vol. 17 (1), pp. 1425-1437. Date of Electronic Publication: 2022 Sep 05 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: De Gruyter Open Country of Publication: Poland NLM ID: 101672167 Publication Model: eCollection Cited Medium: Print ISSN: 2391-5463 (Print) NLM ISO Abbreviation: Open Med (Wars) Subsets: PubMed not MEDLINE

A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors.

Authors: Huo G Wang Y Chen J et al.

Source: Frontiers in oncology [Front Oncol] 2021 May 25; Vol. 11, pp. 692136. Date of Electronic Publication: 2021 May 25 (Print Publication: 2021).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

TWF1 induces autophagy and accelerates malignant phenotype in lung adenocarcinoma via inhibiting the cAMP signaling pathway.

Authors: Wang Y Zuo R Huo G et al.

Source: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2023 Jul; Vol. 37 (7), pp. e23051.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE

Thanks to reviewers 2021.

Source: Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Feb2022.

Journal Info: Publisher: Springer Nature ISSN: 1699-048X